This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goodson, B.
Right arrow Articles by Winter, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goodson, B.
Right arrow Articles by Winter, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 1999, p. 1429-1434, Vol. 43, No. 6
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Characterization of Novel Antimicrobial Peptoids

Bob Goodson,1 Anton Ehrhardt,2 Simon Ng,1 John Nuss,1 Kirk Johnson,1 Marty Giedlin,1 Ralph Yamamoto,1 Walter H. Moos,1,dagger Anke Krebber,1 Martha Ladner,1 Mary Beth Giacona,1 Charles Vitt,1 and Jill Winter1,*

Chiron Corporation, Emeryville, California 94608-2916,1 and Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology, Creighton University School of Medicine, Omaha, Nebraska 681782

Received 5 August 1998/Returned for modification 1 October 1998/Accepted 7 April 1999

Peptoids differ from peptides in that peptoids are composed of N-substituted rather than alpha-carbon-substituted glycine units. In this paper we report the in vitro and in vivo antibacterial activities of several antibacterial peptoids discovered by screening combinatorial chemistry libraries for bacterial growth inhibition. In vitro, the peptoid CHIR29498 and some of its analogues were active in the range of 3 to 12 µg/ml against a panel of gram-positive and gram-negative bacteria which included isolates which were resistant to known antibiotics. Peptoid antimicrobial activity against Staphylococcus aureus was rapid, bactericidal, and independent of protein synthesis. beta -Galactosidase and propidium iodide leakage assays indicated that the membrane is the most likely target of activity. Positional isomers of an active peptoid were also active, consistent with a mode of action, such as membrane disruption, that does not require a specific fit between the molecule and its target. In vivo, CHIR29498 protected S. aureus-infected mice in a simple infection model.


* Corresponding author. Mailing address: Chiron Corporation, 4560 Horton St., Emeryville, CA 94608-2916. Phone: (510) 923-3642. Fax: (510) 923-4115. E-mail: Jill_Winter{at}cc.chiron.com.

dagger Present address: Mito Kor, San Diego, CA 92121.


Antimicrobial Agents and Chemotherapy, June 1999, p. 1429-1434, Vol. 43, No. 6
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.